This is Part Two in my series: “The Power of Persistence.” Last week ... looks good because he is in a two-person lineup and the other person is one of our stock villains. Says Muehl, Muehl points out that the stance of self-deprecating …
Orexigen Therapeutics (NASDAQ: OREX) announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc., Andrx …
Investment Objective The investment seeks long-term capital appreciation. The fund invests at least 80% of its assets in the stocks of companies principally engaged in the development- production- or distribution of products and services …